JP2021500334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500334A5 JP2021500334A5 JP2020521599A JP2020521599A JP2021500334A5 JP 2021500334 A5 JP2021500334 A5 JP 2021500334A5 JP 2020521599 A JP2020521599 A JP 2020521599A JP 2020521599 A JP2020521599 A JP 2020521599A JP 2021500334 A5 JP2021500334 A5 JP 2021500334A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- pharmaceutically acceptable
- tautomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 272
- 150000003839 salts Chemical class 0.000 claims description 70
- 229940126214 compound 3 Drugs 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000013078 crystal Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 208000019838 Blood disease Diseases 0.000 claims description 12
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 12
- 208000014951 hematologic disease Diseases 0.000 claims description 12
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- 229940125782 compound 2 Drugs 0.000 claims description 10
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- 150000001278 adipic acid derivatives Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 claims description 6
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 claims description 6
- 101000877314 Homo sapiens Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 6
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims description 2
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 230000002489 hematologic effect Effects 0.000 claims 1
- 0 CC(CCc(cccc1)c1IC)C*1CCC1 Chemical compound CC(CCc(cccc1)c1IC)C*1CCC1 0.000 description 46
- 238000000034 method Methods 0.000 description 13
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023002371A JP2023036991A (ja) | 2017-10-18 | 2023-01-11 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573917P | 2017-10-18 | 2017-10-18 | |
| US62/573,917 | 2017-10-18 | ||
| PCT/US2018/056428 WO2019079540A1 (en) | 2017-10-18 | 2018-10-18 | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002371A Division JP2023036991A (ja) | 2017-10-18 | 2023-01-11 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500334A JP2021500334A (ja) | 2021-01-07 |
| JP2021500334A5 true JP2021500334A5 (https=) | 2021-10-07 |
Family
ID=66173899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521599A Withdrawn JP2021500334A (ja) | 2017-10-18 | 2018-10-18 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 |
| JP2023002371A Pending JP2023036991A (ja) | 2017-10-18 | 2023-01-11 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023002371A Pending JP2023036991A (ja) | 2017-10-18 | 2023-01-11 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200247790A1 (https=) |
| EP (1) | EP3697762A4 (https=) |
| JP (2) | JP2021500334A (https=) |
| KR (1) | KR20200101330A (https=) |
| CN (1) | CN111417628A (https=) |
| AU (2) | AU2018353122B2 (https=) |
| BR (1) | BR112020007632A2 (https=) |
| CA (1) | CA3079273A1 (https=) |
| CL (1) | CL2020001009A1 (https=) |
| CO (1) | CO2020005944A2 (https=) |
| EA (1) | EA202090959A1 (https=) |
| IL (2) | IL301746B2 (https=) |
| MA (1) | MA50418A (https=) |
| MX (2) | MX2020007152A (https=) |
| SG (1) | SG11202003225YA (https=) |
| WO (1) | WO2019079540A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11225487B2 (en) | 2017-02-17 | 2022-01-18 | Trevena, Inc. | 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
| JP2023546729A (ja) * | 2020-10-27 | 2023-11-07 | トレベナ・インコーポレイテッド | デルタオピオイドモジュレーターの結晶形及び非晶形 |
| WO2025240956A1 (en) * | 2024-05-17 | 2025-11-20 | Yale University | G9a/ehmt2 inhibitor use for prader-willi syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06003054A (es) * | 2003-09-18 | 2006-05-31 | Novartis Ag | 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos. |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| CN103626742B (zh) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| DK3154957T3 (da) * | 2014-06-16 | 2020-02-17 | Fundacion Para La Investig Medica Aplicada | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser |
| EP3157524A4 (en) * | 2014-06-23 | 2017-12-06 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| HUE064145T2 (hu) * | 2016-04-15 | 2024-03-28 | Epizyme Inc | Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok |
| ES2955132T3 (es) * | 2016-12-19 | 2023-11-28 | Epizyme Inc | Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos |
| EP3600318A4 (en) * | 2017-03-31 | 2021-06-09 | Epizyme, Inc. | METHOD OF USING EHMT2 INHIBITORS |
| EP3697420A4 (en) * | 2017-10-18 | 2021-11-24 | Epizyme, Inc. | METHOD OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPY |
-
2018
- 2018-10-18 CA CA3079273A patent/CA3079273A1/en active Pending
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/en not_active Ceased
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/en not_active Withdrawn
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en active Active
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Ceased
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 IL IL301746A patent/IL301746B2/en unknown
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
- 2020-07-13 MX MX2024012124A patent/MX2024012124A/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500334A5 (https=) | ||
| IL273974B2 (en) | Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors, salts thereof and method for their synthesis | |
| JP4530537B2 (ja) | インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| JP2019517487A5 (https=) | ||
| JP2015533176A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2020503303A5 (https=) | ||
| JP2018502925A5 (https=) | ||
| JP2019514854A5 (https=) | ||
| JP2017528487A5 (https=) | ||
| JP2014502641A5 (https=) | ||
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| JP2020517707A5 (https=) | ||
| JP2013544846A5 (https=) | ||
| JP2017525730A5 (https=) | ||
| JP2011500758A5 (https=) | ||
| JP2003525246A (ja) | 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| JP2013542261A5 (https=) | ||
| JP2015505816A5 (https=) | ||
| RU2020109775A (ru) | Комплексная терапия | |
| JP2019534310A5 (https=) | ||
| JP2017524013A5 (https=) | ||
| JPWO2020175629A5 (https=) | ||
| JP2024538117A (ja) | Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。 | |
| JP2020514344A5 (https=) |